Posted by Michael Wonder on 13 Apr 2023
ICER publishes evidence report on treatments for non-alcoholic steatohepatitis
13 April 2023 - Current evidence suggests that resmetirom would achieve common thresholds for cost effectiveness if priced between $39,600–$50,100 per year while obeticholic acid would achieve these thresholds if priced between $32,800-$40,700 per year.
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of resmetirom (Madrigal Pharmaceuticals) and obeticholic acid (Ocaliva, Intercept Pharmaceuticals) for non-alcoholic steatohepatitis.
